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MAN WITH BLURRY VISION
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Case Presentation
A 35 year-old Caucasian man with Pre-B cell ALL on
day 197 post allogenic stem cell transplant and with a
chest tube for pneumothorax post VATS was admitted
for pain at his chest tube site. Sixteen days into his
admission he developed acute onset of blurry vision.
The patient first noticed some difficulty reading a wall
clock when he woke up in the morning followed by a
subsequent worsening of his visual acuity over the next
eight hours. By late afternoon he could only detect
light. Review of systems was significant only for an
intermittent headache over the preceding week.
The patient had a past medical history of pre-B cell
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performed. The pathology from his VATS was
consistent with non-specific interstitial pneumonitis.
His hospitalization post-VATS was complicated by pneumothorax
Radiographic studies
and required chest tube placement which was being cared for at
Figures 1-5 are our patient’s neuroimaging studies performed the
home with the assistance of a visiting nurse.
day he presented with rapid vision loss. While there is no single
pathognomic radiographic finding for PRES, these CT and MRI
On this admission the patient presented to an outside hospital
images demonstrate a series of findings typically suggestive of the
emergency room complaining of pleuritic chest pain and
syndrome.
increasing shortness of breath. Early in his admission he was
empirically started on amphotericin B for suspected fungal
The clinical presentation above confirmed by MRI led to an early
etiology of his pulmonary symptoms. He was also diagnosed with
diagnosis of Posterior Reversible Encephalopathy Syndrome
gastrointestinal graft versus host disease (GVHD) for which he
(PRES) in our patient. The most likely culprit was the
was being treated with steroids and immunosuppressive agents.
cyclosporine he had been taking post stem cell transplant. Both
his cyclosporine and sirolimus were stopped immediately. Our
Medications included cyclosporine, sirolimus, hydrocortisone,
patient’s vision loss persisted four days after the cyclosporine and
Cellcept, Ambisome, Leukine, amikacin, acyclovir, vancomycin,
sirolimus were discontinued. On the fifth day, however, he woke
pentamidine, Dilaudid PCA, acyclovir, Marinol, Nexium, TPN
in the morning reporting a dramatic, complete resolution of his
for nutrition, sliding scale insulin and Zoloft.
visual disturbances.
On physical examination the patient’s temperature was 98.3º F,
Discussion
respiratory rate was 16, blood pressure was 146/107 mmHg, pulse
Posterior Reversible Encephalopathy Syndrome (PRES)
was 71 and pulse oximetry was 96% on room air. His head, neck,
The classic clinical syndrome includes headache, visual changes,
heart and lung examination were unremarkable. He had a chest
confusion, lethargy and seizures. The headache is typically
tube to water seal. His abdominal exam was significant for an
described as constant, bilateral, moderate and dull in quality. Visual
ileostomy draining brown liquid stool. While he was alert and
changes can progress to complete visual loss or may manifest as
oriented to person, place and time, he was confused and answered
visual hallucinations. Fundoscopic exam is usually normal as was
questions inappropriately. His speech was normal and he did not
seen in our patient. Neurologic exam rarely reveals any focal
have any focal neurologic deficits. His pupils were equal, round
deficits. Seizures usually present as generalized tonic clonic.
and reactive to light, extra ocular movements could not be assessed
secondary to his poor visual acuity and there were no signs of
Little can yet be confirmed about the incidence of or risk factors
increased intracranial pressure by dilated funduscopic exam.
for this syndrome since a significant portion of what is known is
based on published case reports. PRES is most commonly seen as a
Laboratory studies on the day of presentation revealed a complete
complication of hypertensive encephalopathy, eclampsia and
blood count within normal limits. Serum electrolytes and
cytotoxic and immunosuppressant medications (most notably
creatinine were unremarkable. Cyclosporine and sirolimus levels
cyclosporine, tacrolimus and interferon) but there is a long list of
were within the appropriate range.
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Figure 3. Diffusion weighted image
of the occipital lobes is normal.
Cytotoxic edema secondary to tissue
ischemia is excluded with this
sequence.

Figure 4. Post-contrast axial T1
weighted image shows patchy
enhancement of the occipital lobes,
consistent with disruption of the blood
brain barrier.

documented etiologies. These varying clinical scenarios are most
clearly unified by the neuroimaging findings seen on CT scanning
and MRI. While cyclosporine is the most common medication
associated with PRES, it is unclear what specific trigger initiates the
syndrome in any particular patient. PRES can develop within days
or many months after exposure and serum levels of cyclosporine
also seem to be a poor predictor of risk for the syndrome.
There are multiple hypotheses concerning the pathogenesis of
PRES but most of the literature describes the syndrome as the
result of impaired cerebral autoregulation and endothelial
dysfunction. The most plausible hypothesis is that, as the body’s
ability to maintain constant cerebral perfusion is impaired or
exceeded, increases in systemic blood pressure could lead to
extravasation of fluid into the surrounding tissue causing vasogenic
edema. Endothelial dysfunction may also contribute since PRES
seems to occur with higher frequency in patients with chronic renal
failure, vasculitis, sepsis and hemolytic uremic syndrome.
Care must be taken to exclude other equally serious diagnoses
such as embolic stroke, venous thrombosis, metabolic
encephalopathy, encephalitis, vasculitis or demyelinating
disorders. This can best be accomplished with neuroimaging
including CT scanning and MRI. Most frequently seen is
symmetrical white matter edema in the parieto-occipital regions
as noted in Figures 1-5.
Appropriate treatment requires discontinuation of the offending
agent or treatment of the underlying disease. Despite optimal care,
some patients sustain permanent vision loss or epilepsy secondary
to PRES. In the majority of cases, however, clinicians can expect
resolution of PRES in days to weeks. Blood pressure should be

Figure 5. Post-contrast sagittal T1
weighted image demonstrates patchy
enhancement of the occipital lobe.

tightly maintained in the normal range with titratable parenteral
agents such as nicardipine or labetalol. Current guidelines for
treating malignant hypertension should be incorporated into the
management of the patient when applicable. Steroids are used in
some settings but are not widely accepted as an appropriate
treatment because of the associated risk of worsening hypertension
and fluid overload. Neuroimaging will also document resolution
of PRES correlating well with the patient’s symptoms. The
offending agent should never be reintroduced to the patient.
The acute development of seizures, visual disturbances, headache
or confusion especially in a patient with hypertension, taking
immunosuppressive or cytotoxic agents or with impaired renal
function should prompt an urgent CT scan and MRI to evaluate
for PRES. This syndrome, while usually reversible in days to weeks
following treatment of the underlying process or withdrawal of
the culprit medication, has the potential to remain permanent
resulting in significant disability if there is a delay in appropriate
diagnosis and treatment.
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